Pharmaceutical Executive
Americans take top spots in disease prevalence
A new study comparing the prevalence of different diseases in the United States and Europe has not received the media coverage it deserves. The paper by Kenneth Thorpe, David Howard, and Katya Galactionova, published online by Health Affairs (October 2, 2007), concluded that "disease prevalence rates...for 10 of the most costly conditions...for the noninstitutionalized population age 50 and older...are much higher in the United States than in these [10] European countries."
Sick Americans by the Numbers: Eight of 10 common diseases are more prevalent in noninstitutionalized Americans age 50 and up than among those in Austria, Denmark, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, and Switzerland
This conclusion was based on Organization for Economic Co-operation and Development data (see chart, below). These findings are consistent with another piece of research published in Journal of the American Medical Association (May 3, 2006) by James Banks, Michael Marmot, Zoe Oldfield, and James Smith that compared both self-reported illnesses and biological markers of disease among non-Hispanic whites age 55 to 64 in England and the United States. They concluded that "based on self-reported illnesses and biological markers [my italics] of disease, US residents are much less healthy than their English counterparts and these differences exist at all points of the SES (socioeconomic status) distribution."
These dramatic findings trigger the obvious question: Why are the numbers so much higher here? One attractive hypothesis is that Americans are merely more likely to be diagnosed with diseases because of the more aggressive testing in this country.
However, this hypothesis could at best explain only part of the difference. The use of biological markers in the US/England study confirmed that these differences are real, not just based on different patterns of diagnosis. Furthermore, the fact that the United States has fallen in international rankings of life expectancy from No. 11 to No. 42 over 20 years strongly suggests that Americans really are less healthy than people in most other affluent countries.
Other factors mentioned by the authors are differences in obesity, lifestyles, health insurance, childhood experiences, and income inequality.
My favorite hypothesis—based on the work of Michael Marmot and others, but barely hinted at in these papers—is stress. Having lived and worked on both sides of the Atlantic, it would not surprise me if Americans were substantially more stressed than Europeans. Americans work longer hours, have fewer vacation days, have a weaker safety net, and have greater income inequality than Europeans. There is growing evidence that stress can weaken the immune system and increase the likelihood of many diseases.
It will probably take years to understand this issue. Meanwhile, both teams of researchers conclude that we need—guess what?—to do more research.
Humphrey Taylor is chairman of the Harris Poll, Harris Interactive. He can be reached at htaylor@harrisinteractive.com
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.